Skip to main content

Table 1 Patient characteristics

From: Periostin levels and eosinophilic inflammation in poorly-controlled asthma

Number

83

Age, mean (range)

61 (21–82)

Sex, male (%)

42 (51)

BMI, mean (SD)

30.0 (5.5)

Atopy, n (%)

61 (73)

Ex-smoker, n (%)

34 (41)

Pack years, median (q1,q3)

26 (2,40)

FEV1 % predicted, mean (SD)

72.2 (20.3)

FEV1/FVC, mean (SD)

0.66 (0.12)

GINA treatment step n (%)

 

3

14 (17)

4

67 (81)

5

2 (2)

ACQ6, mean (SD)

1.83 (0.82)

ICS dose μg, median (q1,q3)

1000 (800,2000)

Taking regular OCS, n (%)

3 (4)

Sputum eosinophils %, median (q1,q3)

2.1 (0.5,9.5)

Blood eosinophils, x109/mL, median (q1,q3), n = 67

0.23 (0.11, 0.40)

  1. BMI body mass index, ACQ6 Asthma Control Questionnaire 6, ICS inhaled corticosteroid dose (in CFC beclomethasone equivalents), OCS oral corticosteroids